PerkinElmer, Inc. (PKI) - NYSE
  • Jan. 29, 2015, 4:21 PM
    • PerkinElmer (NYSE:PKI): Q4 EPS of $0.85 beats by $0.07.
    • Revenue of $608.4M (+2.8% Y/Y) beats by $7.87M.
    • Shares +1.4%.
    | Jan. 29, 2015, 4:21 PM
  • Jan. 6, 2014, 2:45 PM
    • PerkinElmer (PKI +1.5%) gets an upgrade to Outperform from Market Perform at Cowen.
    • Price target lifted to $47 from $35.20.
    | Jan. 6, 2014, 2:45 PM | 1 Comment
  • May 10, 2013, 3:45 PM

    PerkinElmer (PKI +1.2%) introduces a new version of Lead Discovery for the Tibco Spotfire software platform, which, when combined with the Tibco Spotfire software's advanced data visualization and analysis capabilities, brings a new level of chemical intelligence to the informatics platform for advanced scientific discovery. The new version, called Lead Discovery 5.1, uses PKI's ChemDraw drawing tool to improve the capabilities of data analysis with new functionality built to assist chemists.

    | May 10, 2013, 3:45 PM
  • Apr. 26, 2013, 1:03 PM
    Midday top 10 gainers: LOGM +24%. LAS +17%. CTCT +16%. NR +15%. DQ +15%. WBSN +14%. QLIK +13%. CPGI +13%. SPWR +12%. CSIQ +12%.
    Midday top 10 losers: DYAX -32%. HXM -23%. DLA -16%. IKAN -16%. KEG -15%. FALC -14%. COBR -13%. PKI -13%. XIDE -12%. MMSI -12%.
    | Apr. 26, 2013, 1:03 PM
  • Apr. 26, 2013, 11:48 AM

    ISI's Ross Muken downgrades PerkinElmer (PKI -11.7%) to Buy from Strong Buy after the company's Q1 miss. "This is a pretty terrible outcome from at least [an] earnings and operating income standpoint," Muken said on the call after asking management if they have "a hold" on where business is and what caused "pullbacks in demand." CEO Robert Friel cited a political shakeup for weakness in Japan and said he is still "fairly bearish on Europe." ISI's new price target: $36. (transcript)

    | Apr. 26, 2013, 11:48 AM
  • Apr. 26, 2013, 9:11 AM
    Premarket gainers: LOGM +19%. AVNR +16%. SYNA +17%. QLIK +12%. CRIS +9%. DHI +7%. THRX +7%. MUX +7%. JCP +7%. CSTR +6%.
    Losers: PKI -14%. SIMO -11%. BIDU -9%. KEG -8%. SDT -5%
    | Apr. 26, 2013, 9:11 AM
  • Apr. 25, 2013, 5:55 PM
    After-hours top gainers, as of 5:15 p.m.: SYNA +18%. LOGM +15%. QLIK +13%. AMKR +10%. INFA +9%.
    After-hours top losers: PKI -14%. ECHO -8%. CDNS -7%. CLGX -7%. MCRS -7%.
    | Apr. 25, 2013, 5:55 PM
  • Apr. 25, 2013, 5:10 PM

    More on PerkinElmer's (PKI) Q1: Shares grind 14% lower in late trading after earnings miss on the top and bottom line. Adjusted operating profit margins fall to 12.6% from 15.6% in Q1 2012. The company says it experienced "significant headwinds" in Europe and Japan. Adjusted operating income from the Environmental Health segment falls 31.5% Y/Y, while operating profit margins in the unit shed 160 basis points. PKI sees FY13 non-GAAP EPS of $2.00-2.10 — analysts expect $2.29. (PR)

    | Apr. 25, 2013, 5:10 PM
  • Apr. 25, 2013, 4:34 PM
    PerkinElmer (PKI): Q1 EPS of $0.36 misses by $0.12. Revenue of $505.4M (-1% Y/Y) misses by $27.51M. Shares -11.6% AH. (PR)
    | Apr. 25, 2013, 4:34 PM
  • Aug. 3, 2012, 12:55 PM
    Shares of PerkinElmer (PKI +9%) rally after beating on its Q2 EPS target this morning. Net earnings increased 13% Y/Y on double-digit revenue growth in its health care business and stronger margins. Revenue from its human health business rose 18%, while its environmental health segment saw an anemic 1.2% increase. Gross margins also rose to 45.8% from 43.7%.
    | Aug. 3, 2012, 12:55 PM
  • Jun. 19, 2012, 3:53 PM

    PerkinElmer (PKI +3%) holds on to gains late in the day after being upgraded to Conviction Buy on valuation at Goldman this morning, citing its margin expansion potential and low NIH funding. Price target is $34.

    | Jun. 19, 2012, 3:53 PM
  • Feb. 3, 2012, 2:27 PM

    Impressed by PerkinElmer's (PKI +7%) "shock and awe" Q4 results, Jefferies raises its earnings estimates and price target to $27 from $23. "Our focus remains on PKI's ability to consistently drive OP margin expansion," the firm says. The provider of equipment for genetic screening and drug research forecasts 2012 EPS of $1.98-$2.04 vs. $1.91 consensus.

    | Feb. 3, 2012, 2:27 PM
  • Feb. 3, 2012, 9:46 AM

    Shares of PerkinElmer (PKI +4.4%) gain steam off of a Q4 earnings beat and the firm's improved outlook for 2012. The company now sees EPS of $1.98-$2.04, higher than the consensus estimate mark of analysts of $1.92.

    | Feb. 3, 2012, 9:46 AM
  • Oct. 7, 2011, 2:52 PM

    Illumina's (ILMN -32.2%) warning is taking a heavy toll on many companies dependent on medical research spending (I, II). Some of the other names tanking in sympathy: PKI -7.8%. LMNX -7.3%. TMO -5.7%. BRKR -3.5%. WAT -8%. PACB -11.4%. Fluidgm (FLDM -7.8%) is also among the casualties in spite of reaffirming its 2011 outlook.

    | Oct. 7, 2011, 2:52 PM
Company Description
PerkinElmer, Inc. (United States) engages in the provision of products and solutions to diagnostics, research, and laboratory services. it operates through the Human Health and Environmental Health segments. The Human Health segment researches and develops therapies such as genetic disorder... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States